DUPIXENT: First and Only Treatment of Its Kind

DUPIXENT is the first and only biologic treatment for patients aged 6 years and older with uncontrolled moderate-to-severe atopic dermatitis to inhibit the signaling of IL-4 and IL-13, Type 2 cytokines.1,2

  • Both IL-4 and IL-13 are key mediators of type 2 inflammation and impact skin barrier dysfunction3-6

A Dual Inhibitor of IL-4 and IL-13 Signaling, Administered Via Injection2

  • Immunosuppressive agents may inhibit multiple pathways5,7

See How it Works

Identifying Patients With Uncontrolled Moderate-to-Severe Atopic Dermatitis

When topical prescription therapies are not enough, consider DUPIXENT to help your
appropriate patients who are struggling to control their disease.

Identify Patients

Image of an actual patient with atopic dermatitis. Not a clinical trial patient.

Frequently Asked
Questions
Have questions? Get answers to some of
the most commonly asked questions.
Get Answers
Dosing and
Administration
Thinking about prescribing
DUPIXENT? Find the information you
need to get started.
Start Now
Connect With a Rep Have questions about DUPIXENT? Get
answers from a representative.
Request a Visit
References:
  1. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  2. DUPIXENT Prescribing Information.
  3. Palomares O, Akdis M, Martín-Fontecha M, Akdis CA. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. Immunol Rev. 2017;278(1):219-236.
  4. Weidinger S, Beck LA, Bieber T, Kabashima K, Irving AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018- 0001-z
  5. Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37:14. doi:10.1186/s41232-017-0044-7
  6. Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65-S76.